08.04.26 -- STREAM Edition: When Great Biology Meets Manufacturing Reality

A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

As CAR-T manufacturing evolves, QC strategies must adapt. Learn how identity, potency, sterility, and safety testing support faster release decisions and broader patient access.

Consistent vessel design, sparging, and bag materials across 1L to 5,000L volumes enable predictable bioreactor scale-up from development through commercial manufacturing.

 

Reduce manufacturing variability and risk in viral vector production. See how applying Design of Experiment principles with expert guidance stabilizes AAV scale-up efforts.

Single-use consumables can influence cost per therapy, validation risk, and scalability. Gain a practical perspective on spotting cost and risk signals early before they become barriers later.

During this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, cover why elegant biological designs often struggle during process development and commercial scale up.